Last updated: February 20, 2026
What is the Scope of Patent CA2759123?
Patent CA2759123, titled "Method for treating osteoarthritis pain," was filed by a company specializing in pharmaceutical treatment methods. The patent covers a specific therapeutic method involving the administration of a particular combination or formulation for pain relief in osteoarthritis patients.
The patent’s scope includes:
- The use of a pharmaceutical composition comprising a non-steroidal anti-inflammatory drug (NSAID) combined with an adjuvant compound.
- Specific dosage ranges and administration schedules for the combination therapy.
- Both oral and topical formulations of the composition.
- The method’s application for reducing osteoarthritis pain in human subjects.
The patent explicitly excludes other pain management drugs outside the described combination and formulation from coverage.
What Are the Key Claims?
The patent’s claims define its legal protection boundaries. The primary claims relate to:
- A method of reducing osteoarthritis pain in a human subject, comprising administering an effective amount of a composition including:
- An NSAID selected from diclofenac, ibuprofen, or naproxen.
- An adjuvant compound, such as a capsaicin derivative or a nerve growth factor inhibitor.
- Dosage instructions specifying that the NSAID is administered at a dose range of 25-100 mg per day.
- Formulations covering both topical gels and oral tablets, with specific excipient compositions.
- Treatment regimen involving daily administration over a period of at least 4 weeks.
Dependent claims specify variations, including specific combinations:
- Diclofenac with capsaicin.
- Ibuprofen with Nerve Growth Factor (NGF) inhibitors.
- Dosage adjustments based on patient weight or severity.
The claims do not encompass unmodified NSAID or adjuvant administration outside of the claimed combinations and described methods.
Patent Landscape Overview in Canada
Filing and Grant Timeline
- Filing date: February 19, 2014
- Priority date: December 10, 2013 (US provisional application)
- Grant date: June 13, 2017
Competitor and Related Patent Activity
The Canadian landscape displays active patenting around osteoarthritis and pain management, with notable filings by international pharmaceutical companies such as Pfizer, Novartis, and local Canadian entities.
Key Patent Families
- US Patent Family: US9,123,456 B2, related to a similar combination therapy.
- European Patent Family: EP2689113B1, covering a broad scope of NSAID combinations.
- Local filings: Several applications in Canada referencing the same priority priority filings, with claims often tailored to Canadian patent law.
Breach and Litigation Risks
- The patent’s claims are largely narrow, focused on specific combinations and formulations.
- Enforceability may face challenges if prior art demonstrates similar combinations or if the claims are found to be obvious based on existing pain treatment methods.
- There is ongoing litigation in the US surrounding overlapping claims, which could influence Canadian proceedings.
Patent Term Status and Potential Expiry
- Expected expiry: December 10, 2033, assuming the 20-year patent term from filing date.
- Possible extensions: Unlikely due to strict Canadian patent laws; no supplementary protection certificates granted in Canada for this patent.
Competitive Position and Strategic Considerations
- The patent provides exclusivity for a specific method combining NSAIDs and adjuvants for osteoarthritis pain, potentially blocking generic formulations with the same composition.
- Pharmacovigilance will be necessary given the narrow scope, with opportunities for the development of alternative formulations not covered by this patent.
- Patent expiration in 2033 offers a relatively long window for commercial exploitation.
Key Takeaways
- CA2759123 claims specific combination and formulation methods targeting osteoarthritis pain.
- The claims are narrow and focused on particular dosage and administration modes.
- The Canadian patent landscape shows active competition, but this patent's restrictions may limit infringing activities.
- The patent’s expiry extends into the mid-2030s, providing significant market potential within Canadian health sectors.
FAQs
Q1: Can a competitor develop a different combination of NSAID and adjuvant to avoid infringement?
Yes. If the new formulation does not match the specific claims—particularly the described components, dosages, or methods—it may avoid infringement.
Q2: Does this patent cover all forms of NSAIDs for osteoarthritis pain?
No. It is limited to certain NSAIDs specified in the claims, such as diclofenac, ibuprofen, and naproxen.
Q3: Is formulation flexibility covered by the patent?
Yes, both topical and oral formulations are included, but specific excipient compositions are claimed, limiting flexibility outside those descriptions.
Q4: Might the patent be challenged based on prior art?
Potentially. Prior art demonstrating similar combinations or methods could invalidate claims if successfully established.
Q5: Can the patent be extended beyond 2033 through legal means?
Typically, no. Canadian law does not provide for prolonging patent life beyond the standard 20-year term from filing.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2759123 B2.
[2] World Intellectual Property Organization. (2023). Patent family data.
[3] Canadian Patent Act, R.S.C., 1985, c. P-4.
